Docent / Forskare
marianne [dot] jansson [at] med [dot] lu [dot] se
Publikationer (hämtat ur Lunds universitets publikationsdatabas)
- Automated image-based assay for evaluation of HIV neutralization and cell-to-cell fusion inhibition
- Boosting of HIV-1 Neutralizing Antibody Responses by a Distally Related Retroviral Envelope Protein.
- Effect of HIV-2 infection on HIV-1 disease progression and mortality.
- Faster progression to AIDS and AIDS-related death among seroincident individuals infected with recombinant HIV-1 A3/CRF02_AG compared to sub subtype A3.
- Increased survival among HIV-1 and HIV-2 dual-infected individuals compared to HIV-1 single-infected individuals
- T-bet and Eomes Are Differentially Linked to the Exhausted Phenotype of CD8+ T Cells in HIV Infection.
- Toll-Like Receptor 3 Signalling Up-Regulates Expression of the HIV Co-Receptor G-Protein Coupled Receptor 15 on Human CD4(+) T Cells.
- Characterization of humoral responses to soluble trimeric HIV gp140 from a clade A Ugandan field isolate
- Effect of Complement on HIV-2 Plasma Antiviral Activity Is Intratype Specific and Potent
- Frequent intratype neutralization by plasma immunoglobulin A identified in HIV-2 infection.
- R5 HIV-1 with efficient DC-SIGN use is not selected for early after birth in vertically infected children.
- Selected HIV-1 Env Trimeric Formulations Act as Potent Immunogens in a Rabbit Vaccination Model
- Short-term HIV-1 treatment interruption is associated with dysregulated TLR-stimuli responsiveness.
- Dual R3R5 tropism characterizes cerebrospinal fluid (CSF) HIV-1 isolates from individuals with high CSF viral load.
- Dual R3R5 tropism characterizes cerebrospinal fluid HIV-1 isolates from individuals with high cerebrospinal fluid viral load
- Inhibition of HIV-1 disease progression by contemporaneous HIV-2 infection.
- Mycobacteria-infected bystander macrophages trigger maturation of dendritic cells and enhance their ability to mediate HIV transinfection
- Potent Intratype Neutralizing Activity Distinguishes Human Immunodeficiency Virus Type 2 (HIV-2) from HIV-1
- Tuberculosis and HIV Co-Infection
- Increased sensitivity to neutralizing antibodies of end-stage disease R5 HIV-1 is concomitant with reduced gp120 glycosylation and increased plus charge
- Large but not small copy-number alterations correlate to high-risk genomic aberrations and survival in chronic lymphocytic leukemia: a high-resolution genomic screening of newly diagnosed patients.
- Microbial Translocation Correlates with the Severity of Both HIV-1 and HIV-2 Infections
- Broadly cross-neutralizing activity in plasma of HIV-1 and HIV-2 infected individuals
- Comparison of HIV neutralization assays for use in vaccine research and clinical trials, phase II: results from the NeutNet working group
- Mode of Coreceptor Use by R5 HIV Type 1 Correlates with Disease Stage: A Study of Paired Plasma and Cerebrospinal Fluid Isolates.
- Studies on toll-like receptor stimuli responsiveness in HIV-1 and HIV-2 infections
- Evolution of DC-SIGN use revealed by fitness studies of R5 HIV-I variants emerging during AIDS progression
- Primary HIV-1 R5 isolates from end-stage disease display enhanced viral fitness in parallel with increased gp120 net charge.
- Suppression of HIV replication in vitro by CpG and CpG conjugated to the non toxic B subunit of cholera toxin
- Coreceptor usage of primary HIV type 1 isolates obtained from different lymph node subsets
- Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylation
- Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency.